Sales and Marketing

Showing 15 posts of 11524 posts found.

Cross-functional marketing leadership

November 1, 2010 Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing

Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …
AstraZeneca

Patent expiries bite into AstraZeneca revenues

October 29, 2010 Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel

Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …

MabThera gains maintenance therapy licence

October 29, 2010 Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

Watson submits Crestor copycat

October 28, 2010 Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent

 Watson Pharmaceuticals is seeking to launch a generic version of  AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …

Rep’s shotgun request misfires

October 28, 2010 Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis

Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010 Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …

£600m confirmed for three year Cancer Drugs Fund

October 27, 2010 Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010 Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …

Minister confirms NICE will be sidelined in drug evaluation

October 26, 2010 Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing

A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …

Sowing into Good Ground: Using “personalized medicine” for optimal treatment value

October 26, 2010 Sales and Marketing Kinapse, White paper

As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010 Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …

Arena’s obesity treatment lorcaserin rejected by FDA

October 25, 2010 Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity

A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …

Two thirds of pharma companies face ‘strategic crisis’

October 25, 2010 Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales

The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …

Empowering patients through telehealth

October 25, 2010 Sales and Marketing George MacGinnis, Henry Rivera, Michael Dillon, NHS telehealth, Whole System Demonstrators, diabetes telehealth, pa consulting, patients, telehealth

Current models of healthcare are becoming unsustainable all over the world, due to people living longer with chronic diseases, and …

FDA rejects Viropharma’s Cinryze manufacturing expansion

October 25, 2010 Sales and Marketing Cinryze, FDA, FDA complete response letter, Viropharma, angioedema, pharmaceutical manufacturing

ViroPharma was dealt a blow late last week when the FDA turned down its application for additional manufacturing capacity for …
The Gateway to Local Adoption Series

Latest content